
MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC
Keywords: NSCLC, non-small cell lung cancer; MCL-1, Myeloid cell leukemia-1; IC50, half maximal inhibitory concentration; CDDP, cisplatin; MMP, mitochondrial membrane potential; CPR-A549, cisplatin resistant A549; DMEM, Dulbecco's modified Eagle medium; MTT, 3-(4,5